$19.18
-0.07-0.36%
Last update: Oct 19, 8:08 AM
$19.21
-0.04-0.21%
Amneal Pharmaceuticals Inc
AMRXNASDAQ
Amneal Pharmaceuticals (AMRX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Amneal Pharmaceuticals (AMRX) last issued guidance on July 30, 2026 for fiscal year 2026. The company guided earnings per share in the range of $0.96 - $1.06, compared to a consensus EPS estimate of $0.97. Amneal Pharmaceuticals also guided revenue in the range of $3.1B - $3.2B for the period.
Compared to prior guidance, Amneal Pharmaceuticals raised its EPS outlook from a previous range of $0.95 - $1.05. On the revenue side, the company raised its revenue forecast from a prior range of $3.05B - $3.15B.
Amneal Pharmaceuticals has issued 26 guidance updates between November 4, 2022 and July 30, 2026. During this period, the company raised its outlook 11 times and lowered it 4 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.23 | $0.17 | $0.18 | $0.13 |
| Actual | $0.30 | $0.27 | $0.21 | $0.17 |
| Surprise | +30.4% | +58.8% | +16.7% | +30.8% |
| Revenue | ||||
| Estimate | $765.7M | $715.4M | $810.7M | $773.7M |
| Actual | $796.2M | $722.5M | $814.3M | $784.5M |
| Surprise | +3.98% | +1.00% | +0.44% | +1.39% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.23 | $0.22 | $0.24 | $0.28 |
| Revenue | ||||
| Consensus | $812.6M | $827.5M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $0.30 | $0.23 | 30.4 % |
| Q1 | May 7, 2026 | $0.27 | $0.17 | 58.8 % |
| Q4 | Feb 27, 2026 | $0.21 | $0.18 | 16.7 % |
| Q3 | Oct 30, 2025 | $0.17 | $0.13 | 30.8 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Jul 30, 2026 | $796.20M | $765.70M | 3.98 % |
| Q1 | May 7, 2026 | $722.52M | $715.38M | 1.00 % |
| Q4 | Feb 27, 2026 | $814.32M | $810.74M | 0.44 % |
| Q3 | Oct 30, 2025 | $784.51M | $773.73M | 1.39 % |
